PLG and prostate cancer: suPAR can be used as an effective molecular scavenger of uPA in human prostate cancer cells with high uPA-uPAR expression (34), and an increase in suPAR is related to plasminogen inhibition in patients with paroxysmal nocturnal hemoglobinuria (27).